Aktis Oncology, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKTS Nasdaq 2836 www.aktisoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aktis Oncology, Inc.

Aktis Oncology to Present at the Jefferies Global Healthcare Conference - May 27th, 2026 2:05 pm
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - May 25th, 2026 1:05 pm
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - May 21st, 2026 3:21 pm
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - May 13th, 2026 2:30 pm
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - May 11th, 2026 2:01 pm
Aktis Oncology to Present at the BofA Securities Health Care Conference - May 6th, 2026 6:00 am
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors - May 5th, 2026 8:14 am
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - May 4th, 2026 2:05 pm
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Apr 26th, 2026 7:04 am
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 21st, 2026 3:00 pm
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Apr 17th, 2026 7:55 am
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors - Apr 16th, 2026 6:00 am
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 - Apr 12th, 2026 3:18 pm
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - Mar 30th, 2026 2:01 pm
Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs - Mar 9th, 2026 9:05 pm
Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference - Mar 3rd, 2026 6:02 pm
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Feb 25th, 2026 7:13 am
Aktis Oncology to Present at Upcoming March Investor Conferences - Feb 24th, 2026 2:05 pm
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Feb 24th, 2026 6:00 am
Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls - Feb 3rd, 2026 7:34 am